Alnylam Canada ULC is pleased to announce that OXLUMO® (lumasiran) is now funded across Canada through both public and ...

Panelists discuss how integrating subcutaneous (SubQ) therapies into oncology practice involves thorough economic evaluation, ...

Over the past decade, several novel immunotherapies have transformed the treatment landscape of relapsed or refractory B-cell acute lymphoblastic leukaemia. In the pivotal TOWER trial, blinatumomab—a ...

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Nektar Therapeutics (NASDAQ: NKTR) stock exploded nearly 157% following news that Rezpeg, the company’s experimental ...

The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab ...

The US FDA has approved GSK's 200 mg/ml autoinjector of Benlysta for individuals aged five years and above with active lupus ...

Children with diabetes who inhaled their mealtime doses of insulin did just as well as those who injected insulin under the ...

GSK’s approval expands belimumab treatment options, offering a first-of-its-kind subcutaneous option that can be administered ...

Subcutaneous injection of zein before skin injury reduced leukocyte number and increased T cells in the wound bed. A, Representative images of skin after immunostaining with anti-α-SMA (myofibroblasts ...